Drawing for TRIUMPH

USPTO serial 97668847

TRIUMPH

Reviewed by CopyMark Law Group

Status 734Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
MCMORROW, JANICE LEE
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 734: Status 734 means the fifth and typically final extension to file a Statement of Use was granted. You must file an acceptable Statement of Use before this last extension expires or the application will abandon.

Need help with TRIUMPH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,246*

Plus Government fees of $600

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nancy Sabarra

Nancy Sabarra FROSS ZELNICK LEHRMAN & ZISSU, P.C.151 WEST 42ND ST., 17TH FL.NEW YORK, NY 10036United States

Goods and services

ClassDescriptionStatusFirst use
001Active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research useACTIVE—
005Vaccines; vaccine adjuvants; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cellsACTIVE—
042Pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccinesACTIVE—
044Medical services; medical information; providing a website featuring medical informationACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 17, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 16, 2026EX5GSOU EXTENSION 5 GRANTED—
Aug 13, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 21, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 20, 2026EXT5SOU EXTENSION 5 FILED—
Jan 31, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 30, 2026EX4GSOU EXTENSION 4 GRANTED—
Jan 30, 2026EXT4SOU EXTENSION 4 FILED—
Jan 30, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 9, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 8, 2025EX3GSOU EXTENSION 3 GRANTED—
Aug 8, 2025EXT3SOU EXTENSION 3 FILED—
Aug 8, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 5, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Feb 5, 2025EX2GSOU EXTENSION 2 GRANTED—
Feb 4, 2025EXT2SOU EXTENSION 2 FILED—
Feb 4, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 2, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Aug 2, 2024EX1GSOU EXTENSION 1 GRANTED—
Aug 2, 2024EXT1SOU EXTENSION 1 FILED—
Aug 2, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Feb 13, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 19, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 19, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 29, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 15, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 14, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 13, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 13, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 16, 2023XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Aug 16, 2023XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
May 22, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 22, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 22, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 15, 2023DOCKASSIGNED TO EXAMINER—
Feb 21, 2023AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Feb 21, 2023ALIEASSIGNED TO LIE—
Dec 15, 2022PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Nov 29, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 11, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance